Gilead appoints Dietmar Berger
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
"While advances have been made in the treatment of haemophilia, unmet medical needs still exist," said Dietmar Berger, Sanofi's chief medical officer. "We believe efanesoctocog alfa provides ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback